Skip to main content

Research Repository

Advanced Search

All Outputs (197)

Evaluation of CDK12 protein expression as a potential novel biomarker for DNA damage response–targeted therapies in breast cancer (2017)
Journal Article
Naidoo, K., Wai, P. T., Maguire, S. L., Daley, F., Haider, S., Kriplani, D., …Natrajan, R. (2018). Evaluation of CDK12 protein expression as a potential novel biomarker for DNA damage response–targeted therapies in breast cancer. Molecular Cancer Therapeutics, 17(1), 306-315. https://doi.org/10.1158/1535-7163.mct-17-0760

Disruption of Cyclin-Dependent Kinase 12 (CDK12) is known to lead to defects in DNA repair and sensitivity to platinum salts and PARP1/2 inhibitors. However, CDK12 has also been proposed as an oncogene in breast cancer. We therefore aimed to assess t... Read More about Evaluation of CDK12 protein expression as a potential novel biomarker for DNA damage response–targeted therapies in breast cancer.

Reply to Rosen (2017)
Journal Article
Reis-Filho, J. S., Geyer, F. C., Weigelt, B., Rakha, E. A., Ellis, I. O., & Schnitt, S. J. (2017). Reply to Rosen. Modern Pathology, 30(10), 1505-1506. doi:10.1038/modpathol.2017.70

Altered glutamine metabolism in breast cancer: subtype dependencies and alternative adaptations (2017)
Journal Article
El Ansari, R., McIntyre, A., Craze, M. L., Ellis, I. O., Rakha, E. A., & Green, A. R. (in press). Altered glutamine metabolism in breast cancer: subtype dependencies and alternative adaptations. Histopathology, https://doi.org/10.1111/his.13334

Cancer cells must alter their metabolism in order to satisfy the demands of necessary energy and cellular building blocks. These metabolic alterations are mediated by many oncogenic changes that affect cellular signalling pathways, which result in su... Read More about Altered glutamine metabolism in breast cancer: subtype dependencies and alternative adaptations.

Current trials to reduce surgical intervention in ductal carcinoma in situ of the breast: critical review (2017)
Journal Article
Toss, M., Miligy, I., Thompson, A., Khout, H., Green, A., Ellis, I., & Rakha, E. (2017). Current trials to reduce surgical intervention in ductal carcinoma in situ of the breast: critical review. Breast, 35, 151-156. doi:10.1016/j.breast.2017.07.012

The high proportion of ductal carcinoma in situ (DCIS) presented in mammographic screening and the relatively low risk of progression to invasive disease have raised questions related to overtreatment. Following a review of current DCIS management pr... Read More about Current trials to reduce surgical intervention in ductal carcinoma in situ of the breast: critical review.

Novel immunohistochemistry-based signatures to predict metastatic site of triple-negative breast cancers (2017)
Journal Article
Klimov, S., Rida, P. C., Aleskandarany, M. A., Green, A. R., Ellis, I. O., Janssen, E. A., …Aneja, R. (2017). Novel immunohistochemistry-based signatures to predict metastatic site of triple-negative breast cancers. British Journal of Cancer, 117(6), 826-834. https://doi.org/10.1038/bjc.2017.224

Background: Although distant metastasis (DM) in breast cancer (BC) is the most lethal form of recurrence and the most common underlying cause of cancer related deaths, the outcome following the development of DM is related to the site of metastasis.... Read More about Novel immunohistochemistry-based signatures to predict metastatic site of triple-negative breast cancers.

FOXP1 expression correlates with better prognosis in invasive breast cancer including the ER-positive luminal subtype (2017)
Conference Proceeding
Joseph, C., Craze, M. L., Nolan, C., Diez-Rodriguez, M., Green, A. R., Rakha, E., …Mukherjee, A. (2017). FOXP1 expression correlates with better prognosis in invasive breast cancer including the ER-positive luminal subtype.

Background: Fork head box P1 (FOXP1) is a FOX family transcription factor influencing ERα;-regulated transcription by interaction with the ERα; related pioneer factor FOXA1. Altered FOXP1 expression is seen in breast and prostate cancers. This study... Read More about FOXP1 expression correlates with better prognosis in invasive breast cancer including the ER-positive luminal subtype.

Elevated expression of STK3 mRNA and protein is associated with poor outcome in invasive breast cancer (2017)
Conference Proceeding
Ojiegbe, S., Joseph, C., Provenzano, E., Caldas, C., Nolan, C., Green, A., …Mukherjee, A. (2017). Elevated expression of STK3 mRNA and protein is associated with poor outcome in invasive breast cancer.

Purpose of the study: The mammalian sterile 20-like kinase (MST2/STK3) and its close homologue MST1(STK4) are members of the germinal centre kinase group II (GCK II) family of mitogen-activated protein kinases (MAPK). High STK3 expression is known to... Read More about Elevated expression of STK3 mRNA and protein is associated with poor outcome in invasive breast cancer.

An updated PREDICT breast cancer prognostication and treatment benefit prediction model with independent validation (2017)
Journal Article
Candido Dos Reis, F. J., Wishart, G. C., Dicks, E. M., Greenberg, D., Rashbass, J., Schmidt, M. K., …Pharoah, P. D. (2017). An updated PREDICT breast cancer prognostication and treatment benefit prediction model with independent validation. Breast Cancer Research, 19(1), Article 58. https://doi.org/10.1186/s13058-017-0852-3

BACKGROUND: PREDICT is a breast cancer prognostic and treatment benefit model implemented online. The overall fit of the model has been good in multiple independent case series, but PREDICT has been shown to underestimate breast cancer specific morta... Read More about An updated PREDICT breast cancer prognostication and treatment benefit prediction model with independent validation.

Phenotypic characterization of breast cancer: the role of CDC42 (2017)
Journal Article
Chrysanthou, E., Gorringe, K. L., Joseph, C., Craze, M. L., Nolan, C. C., Diez-Rodriguez, M., …Mukherjee, A. (2017). Phenotypic characterization of breast cancer: the role of CDC42. Breast Cancer Research and Treatment, 164(2), https://doi.org/10.1007/s10549-017-4267-8

Purpose: The molecular landscape of breast cancer (BC), especially of the Luminal A subtype, remains to be fully delineated. Transcriptomic data shows that Luminal A tumours are enriched for aberrant expression of genes in the cell division control 4... Read More about Phenotypic characterization of breast cancer: the role of CDC42.

Chemokine (C-C motif) receptor 7 (CCR7) associates with the tumour immune microenvironment but not progression in invasive breast carcinoma (2017)
Journal Article
Sonbul, S. N., Gorringe, K. L., Aleskandarany, M. A., Mukherjee, A., Green, A. R., Ellis, I. O., & Rakha, E. A. (2017). Chemokine (C-C motif) receptor 7 (CCR7) associates with the tumour immune microenvironment but not progression in invasive breast carcinoma. Journal of Pathology: Clinical Research, 3(2), 105-114. https://doi.org/10.1002/cjp2.65

Some previous studies have reported that the chemokine (C-C motif) receptor 7 (CCR7) plays a role in breast cancer, is associated with lymph node metastasis and drives the site of distant metastasis. However, the impact of its expression on patient o... Read More about Chemokine (C-C motif) receptor 7 (CCR7) associates with the tumour immune microenvironment but not progression in invasive breast carcinoma.

Clinical impact of tumor DNA repair expression and T-cell infiltration in breast cancers (2017)
Journal Article
Green, A. R., Aleskandarany, M. A., Ali, R., Hodgson, E. G., Atabani, S., De Souza, K., …Madhusudan, S. (2017). Clinical impact of tumor DNA repair expression and T-cell infiltration in breast cancers. Cancer Immunology Research, 5(4), 292-299. https://doi.org/10.1158/2326-6066.CIR-16-0195

© 2017 American Association for Cancer Research. Impaired DNA repair drives mutagenicity, which increases neoantigen load and immunogenicity. We investigated the expression of proteins involved in the DNA damage response (ATM, Chk2), double-strand br... Read More about Clinical impact of tumor DNA repair expression and T-cell infiltration in breast cancers.

Androgen dependent mechanisms of pro-angiogenic networks in placental and tumor development (2017)
Journal Article
Metzler, V. M., de Brot, S., Robinson, R. S., Jeyapalan, J. N., Rakha, E., Walton, T., …Mongan, N. P. (2017). Androgen dependent mechanisms of pro-angiogenic networks in placental and tumor development. Placenta, 56, 79-85. https://doi.org/10.1016/j.placenta.2017.02.018

The placenta and tumors share important characteristics, including a requirement to establish effective angiogenesis. In the case of the placenta, optimal angiogenesis is required to sustain the blood flow required to maintain a successful pregnancy,... Read More about Androgen dependent mechanisms of pro-angiogenic networks in placental and tumor development.

Prognostic stratification of oestrogen receptor-positive HER2-negative lymph node-negative class of breast cancer (2016)
Journal Article
Rakha, E. A., Agarwal, D., Green, A. R., Ashankyty, I., Ellis, I. O., Ball, G., & Alaskandarany, M. A. (2017). Prognostic stratification of oestrogen receptor-positive HER2-negative lymph node-negative class of breast cancer. Histopathology, 70(4), 622-631. doi:10.1111/his.13108

Aims Multigene assay is recommended currently for prognostic stratification of the clinically indeterminate group of breast cancer (BC) patients defined as lymph node (LN)?negative, oestrogen receptor (ER)?positive, HER2?negative (LN?/ER+/HER2?) t... Read More about Prognostic stratification of oestrogen receptor-positive HER2-negative lymph node-negative class of breast cancer.

Molecular classification of breast cancer: what the pathologist needs to know (2016)
Journal Article
Rakha, E. A., & Green, A. R. (2017). Molecular classification of breast cancer: what the pathologist needs to know. Pathology, 49(2), 111-119. doi:10.1016/j.pathol.2016.10.012

Breast cancer is a heterogeneous disease featuring distinct histological, molecular and clinical phenotypes. Although traditional classification systems utilising clinicopathological and few molecular markers are well established and validated, they... Read More about Molecular classification of breast cancer: what the pathologist needs to know.

Diagnostic concordance of breast pathologists: lessons from the National Health Service Breast Screening Programme Pathology External Quality Assurance Scheme (2016)
Journal Article
Rakha, E. A., Ahmed, M. A., Aleskandarany, M. A., Hodi, Z., Lee, A. H. S., Pinder, S. E., & Ellis, I. O. (2017). Diagnostic concordance of breast pathologists: lessons from the National Health Service Breast Screening Programme Pathology External Quality Assurance Scheme. Histopathology, 70(4), 632-642. https://doi.org/10.1111/his.13117

Clinicopathological and functional significance of RECQL1 helicase in sporadic breast cancers (2016)
Journal Article
Arora, A., Parvathaneni, S., Aleskandarany, M. A., Agarwal, D., Ali, R., Abdel-Fatah, T., …Madhusudan, S. (2017). Clinicopathological and functional significance of RECQL1 helicase in sporadic breast cancers. Molecular Cancer Therapeutics, 16(1), https://doi.org/10.1158/1535-7163.MCT-16-0290

RECQL1, a key member of the RecQ family of DNA helicases, is required for DNA replication and DNA repair. Two recent studies have shown that germline RECQL1 mutations are associated with increased breast cancer susceptibility. Whether altered RECQL1... Read More about Clinicopathological and functional significance of RECQL1 helicase in sporadic breast cancers.

Breast conservation in ductal carcinoma in situ (DCIS): what defines optimal margins? (2016)
Journal Article
Toss, M. S., Pinder, S. E., Green, A. R., Thomas, J., Morgan, D. A., Robertson, J. F., …Rakha, E. A. (2017). Breast conservation in ductal carcinoma in situ (DCIS): what defines optimal margins?. Histopathology, 70(5), 681-692. https://doi.org/10.1111/his.13116

The introduction of mammographic screening has resulted in a rise in the detection rate of ductal carcinoma in situ (DCIS), currently accounting for one‐fifth of screen‐detected breast cancers. Although 60–70% of DCIS are treated with breast‐conservi... Read More about Breast conservation in ductal carcinoma in situ (DCIS): what defines optimal margins?.

Clinicopathological and molecular characteristics of Ku 70/80 expression in Nigerian breast cancer and its potential therapeutic implications (2016)
Journal Article
Agboola, A. O., Ebili, H. O., Iyawe, V. O., Banjo, A. A., Salami, B. A., Rakha, E. A., …Green, A. R. (2017). Clinicopathological and molecular characteristics of Ku 70/80 expression in Nigerian breast cancer and its potential therapeutic implications. Pathology - Research and Practice, 213(1), 27-33. https://doi.org/10.1016/j.prp.2016.10.005

Ku 70/80 is a regulator of the Non-Homologous End Joining (NHEJ) roles in clinicopathological features, and has prognostic significance in breast cancer (BC) in Caucasian populations. However, its significance in the Nigerian BC population, which is... Read More about Clinicopathological and molecular characteristics of Ku 70/80 expression in Nigerian breast cancer and its potential therapeutic implications.